The subtype CD200-positive, chorionic mesenchymal stem cells from the placenta promote regeneration of human hepatocytes.
Human placental mesenchymal stem cells (hPMSCs), for the treatment of fulminant hepatic failure, have been widely studied. Only a few studies have investigated the effect of the subtype CD200(+)hPMSCs on regeneration of human hepatocytes. CD200(+)hPMSCs can down-regulate activity of several immunocytes and suppress TNF-α secretion from macrophages via the CD200-CD200R axis. We have investigated the influence of CD200-positive human placenta chorionic mesenchymal stem cells (CD200(+)hPCMSCs) on metabolism, proliferation and apoptosis of human hepatocytes in vitro. CD200(+)hPCMSCs promote urea synthesis, albumin secretion and hepatocytes proliferation at co-culture ratios of 1:1 and 3:1. Additionally, CD200(+)hPCMSCs inhibit hepatocyte apoptosis via up-regulation of an anti-apoptotic protein, Bcl-xL. Thus, CD200(+)hPCMSCs can provide supportive benefit for the regeneration of human hepatocytes and also have immunosuppressive properties. Therefore, CD200(+)hPCMSCs may be an ideal candidate for stem cell-based therapy in hepatic failure.